


# TRANSFUSION TRANSMITTED INFECTIONS

## CONTENTS

- TTI ?
- Characteristics of TTI
- Mandatory TTI
- Methods/Technologies for TTI Testing
- TTI Notification
- Why & How To Notify

## TRANSFUSION CHAIN



**TTI = TRANSFUSION TRANSMISSIBLE INFECTIONS**

A pathogen :

- Able to transmit through blood or blood components
- Able to survive outside human body
- Able to survive through range of temperatures
- Able to replicate and re-establish following transfusion
- Exists naturally either free in plasma or in cellular component

## INFECTIOUS AGENTS

1. Virus – most commonly transmitted
2. Bacteria
3. Protozoa
4. Fungi – not accepted as blood donor(too sick)
5. Parasite
6. Prion

## VIRUS

1. Hepatitis: Hep B, Hep C, Hep D
2. Human immunodeficiency virus (HIV)
3. Human T-cell Lymphotropic virus (HTLV-1,2)
4. Epstein barr virus (EBV)
5. Cytomegalo virus (CMV)
6. West Nile virus (WNV)
7. Human herpes virus (HHV)

## BACTERIA

1. Treponema pallidum
2. Yersinia enterocolitica
3. Pseudomonas
4. Propionibacterium acnes
5. Staphylococcus epidermidis
6. Bacillus cereus

## PARASITES

1. Plasmodium species
2. Babesia microti
3. Trypanosoma Cruzi
4. Leishmania species
5. Toxoplasma gondi

## PRIONS

Creutzfeld Jacob disease / Variant Creutzfeld Jacob disease

## CHARACTERISTICS OF TTI

- Asymptomatic or only mild symptoms in donors –hence pass donor screening criteria
- Long incubation period before clinical signs and symptoms appear
- Stability in blood at 4°C or lower
- Might cause a carrier state of infection (HBV, HCV)

## HOW AND WHAT TO TEST ?

- Identify structural protein
- Identify antibody produced
- Identify antigen
- Identify nuclear material

### HOW TO TEST?

- Rapid tests
- ELISA
- Chemiluminescence assay (CLIA)
- Nucleic Acid Amplification Testing (NAT)

## SELECTION OF SCREENING ASSAYS

- What is the test?
- Who is going to use it?
- Is the staff experienced or newly recruited?
- What are the constraints?
- Are resources available?
- Are results needed in a very restricted period of time?
- How is it to be used? Large or small number of specimens?
- What are the existing systems?

## MANDATORY TTI TESTING

Under **Drugs and Cosmetic Act 1940**

Rules 1945 amendments thereafter, (SCH. F, Part XII B)

Ministry of Health And Family Welfare

Government of India

**Screening of each blood & blood components is Mandatory**

- HBsAg
- Anti HIV 1 & 2
- Anti HCV
- VDRL
- Malarial parasite

# MANDATORY TTI TESTING

HIV 1 & 2, Hepatitis C,, Hepatitis B Syphilis & Malaria

1.

Screening for antibodies to HIV-1 & 2

( Rapid/3<sup>rd</sup> or 4<sup>th</sup> generation ELISA /Chemiluminescence and / NAT )
2.

Screening for antibodies to HCV

( Rapid/3<sup>rd</sup> or 4<sup>th</sup> generation ELISA /Chemiluminescence and / NAT )
- 3

Hepatitis B Surface Antigen

( Rapid/ 3<sup>rd</sup> or 4<sup>th</sup> generation ELISA /Chemiluminescence and / NAT )
4.

Syphilis ( TPHA/VDRL/RPR )
5.

Malarial parasite (PBF / Rapid card test )

# MANDATORY BLOOD SCREENING FOR INFECTIOUS MARKERS

Infectious Markers	Year of Enforcement	Mandatory Testing Technology	Newer Technologies
Syphilis	1975	RPR/VDRL/TPHA	ELISA
Hepatitis B virus	1975	ELISA/Rapid	Chemiluminescence/NAT
Malaria	1975	Smear/Rapid	ELISA
HIV	1988	ELISA/Rapid	Chemiluminescence/NAT
Hepatitis C Virus	2001	ELISA/Rapid	Chemiluminescence/NAT

## RECENT CONCERNS

- Latency and carrier state leading to persistent infections: HIV, HBV, HCV were major concerns but Hep A and Hep E
- Emerging infections like Dengue Virus ,West Nile Virus, Zika Virus, and others are posing risk for infection

### VARIOUS TESTING TECHNOLOGIES

Technology	Window Period		
	HIV	HCV	HBV
ELISA-III Generation	20.6 days	58.3 days	36.3 days
ELISA-IV Generation	13.7 days	9.4 days	24 days
ID NAT	5.6 days	4.9 days	20.6 days



## ELISA Testing

**Definition:** Detection of antigen and/or antibody in plasma/serum using an enzyme-linked chromogenic end point detection system.

### Types of ELISA:

- Indirect
- Competitive
- Sandwich
- Capture

### ELISA – Enzyme linked Immunosorbent Assay - Evolution

- **1<sup>st</sup> generation:** Infected cell lysate is used as an antigen.
- **2<sup>nd</sup> generation:** Glycopeptides (Recombinant antigens) are used.
- **3<sup>rd</sup> generation:** Synthetic peptides.
- **4<sup>th</sup> generation:** Synthetic peptides and antibodies.

## IDEAL ELISA PLATE(96 wells) LAYOUT



## RAPID TESTS


**Employ a variety of techniques**

- Dot blot assays
  - Particle agglutination
  - Spot tests
  - Immuno- chromatographic tests or Card Tests
- Most have sensitivities and specificities of 99% and 98% respectively


### Applications of Rapid tests

- Useful in small blood banks
- Useful in emergency

## RAPID IMMUNOCHROMATOGRAPHIC ASSAY




## MALARIA CARD TEST



## CHEMILUMINESCENCE IMMUNOASSAY

- **Principle:** It is the production of light [Luminescence] from an oxidation-reduction chemical reaction.
- Two chemicals react to form an excited (high-energy) intermediate, which breaks down releasing its energy as photons of light and interpreted as Optical density value.



## Preventive strategies for bacterial contamination

- Improved venipuncture site disinfection
- Removal of first aliquot of the donor blood by using bags with diversion pouch.
- Optimizing storage temperature
- Visual inspection of component before use



## **Preventive strategies for TTI (contd...)**

- **Improved pre- transfusion blood testing**
  - Sensitive and specific serological testing
  - Addition of newer methodologies/ better proven kits - added
- **Reducing recipient exposure to blood donor**
  - Optimizing transfusion indications
  - Increased use of single donor products
- **Pathogen inactivation**

## **Preventive strategies for TTI (contd...)**


- **Careful donor selection.**
  - Repeat voluntary blood donors
  - Education counselling and retention of these donors
  - Improvement in the blood donor screening criteria
- **Universal leukocyte reduction**

# DONOR NOTIFICATION

## Why should the donors be informed of test results?


- Results are significant to their health
- Ensures no further donations
- Unethical to hold information
- Informing about Pathology - acute and chronic
  - Secondary transmission - sexual, mother to child
  - Mode of infection-why not excise
  - Treatment and management
- General surveillance and epidemiology
  - acute infection (WP)
  - To improve testing methodology

**NBTC/NACO  
Recommendation**



## HOW TO NOTIFY ?

- Follow NACO/NBTC policy on how to notify donors about positive TTI
- Tell the results on a face-to-face basis
- Counsellor - well-trained in counselling skills
- Given in person, never on telephone
- Maintain confidentiality
- Opportunity to ask questions / discussion
- Further appointment offered



## REFERRAL

- Refer the donor to other sources of advice and support
  - HIV - ICTC (Integrated Counselling and Testing Center)
  - HBV/HCV - Medicine / Gastro/ Hepatologist
  - Syphilis - Dermatology / STD Clinic
  - Malaria - Physician /Medicine

## IMPACT ON BLOOD DONORS

- What will the test result mean?
- Will I become ill?
- What about my partner / offspring?
- Am I infectious?
- How did I become infected?
- Is infection treatable?